



US006410550B1

(12) **United States Patent**
Coe et al.

(10) **Patent No.: US 6,410,550 B1**
(45) **Date of Patent: Jun. 25, 2002**

(54) **ARYL FUSED AZAPOLYCYCLIC COMPOUNDS**

(75) Inventors: **Jotham Wadsworth Coe**, Niantic;
Paige Roanne Palmer Brooks, North
Stonington, both of CT (US)

(73) Assignee: **Pfizer INC**, New York, NY (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/402,010**

(22) PCT Filed: **Nov. 13, 1998**

(86) PCT No.: **PCT/IB98/01813**

§ 371 (c)(1),

(2), (4) Date: **Sep. 28, 1999**

(87) PCT Pub. No.: **WO99/35131**

PCT Pub. Date: **Jul. 15, 1999**

Related U.S. Application Data

(60) Provisional application No. 60/070,245, filed on Dec. 31,
1997.

(51) **Int. Cl.**⁷ **A61K 31/44**; A61K 31/505;
C07D 221/22; C07D 413/00; A61P 1/00

(52) **U.S. Cl.** **514/289**; 514/210.21; 514/228.2;
514/232.8; 514/253.02; 514/253.03; 514/256;
514/281; 514/295; 546/43; 546/74; 546/97;
544/58.2; 544/60; 544/125; 544/126; 544/242;
544/361

(58) **Field of Search** 546/43, 74, 97;
544/58.2, 60, 125, 126, 242, 361; 514/210.21,
228.2, 232.8, 253.02, 253.03, 256, 281,
289, 295

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,471,503 A * 10/1969 Carson 260/294.7

FOREIGN PATENT DOCUMENTS

EP	0 955 301	* 11/1999
EP	1 078 637	* 2/2001
WO	WO 99/55680	* 11/1999
WO	WO 00/44755	* 8/2000
WO	WO 00/45846	* 8/2000

OTHER PUBLICATIONS

Mazzocchi et al., Synthesis and Pharmacological Activity of
2,3,4,5-Tetrahydro1,5 methano-1H-3-benzazepines, Jour-
nal of Medicinal Chemistry, vol. 22, No. 4, pp. 455-457,
1979.*


* cited by examiner

Primary Examiner—Brenda Coleman

(74) *Attorney, Agent, or Firm*—Peter C. Richardson; Paul
H. Ginsburg; Roy F. Waldron

(57) **ABSTRACT**

Compounds of the formula



and their pharmaceutically acceptable salts, wherein R¹, R²,
and R³ are defined as in the specification, intermediates in
the synthesis of such compounds, pharmaceutical composi-
tions containing such compounds and methods of using such
compounds, in the treatment of neurological and psycho-
logical disorders.

15 Claims, No Drawings